A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component

被引:19
作者
Li, Jing [1 ,2 ]
You, Wenjie [3 ]
Zheng, Difan [2 ]
Yan, Bei [1 ]
Ma, Xiao [4 ]
Pan, Yunjian [2 ]
Zhang, Yang [2 ]
Li, Yuan [5 ]
Shen, Xuxia [5 ]
Cheng, Xinghua [2 ]
Sun, Yihua [2 ]
Chen, Haiquan [2 ]
机构
[1] Shandong Police Hosp, Dept Internal Med, Jinan, Shandong, Peoples R China
[2] Fudan Univ, Dept Thorac Surg, Shanghai Canc Ctr, Dong An Rd 270, Shanghai 200032, Peoples R China
[3] Shandong Univ, Dept Resp Med, Shandong Prov Hosp, Jinan, Shandong, Peoples R China
[4] Shanghai Pulm Hosp, Dept Internal Med, Shanghai, Peoples R China
[5] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Lung adenocarcinoma; Solid; FGFR mutation; Prognosis; IASLC/ATS/ERS CLASSIFICATION; INTERNATIONAL-ASSOCIATION; INDEPENDENT PREDICTOR; DRIVER MUTATIONS; SMOKERS VARIES; EGFR MUTATION; SUBTYPE; RECURRENCE; CANCER; FREQUENCY;
D O I
10.1007/s00432-018-2588-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have reported that solid predominant lung adenocarcinoma according to the IASLC/ATS/ERS classification was associated with poor prognosis. However, the correlation of solid component with clinicopathological, molecular features, and prognosis in all lung adenocarcinoma patients remains unexplored. Surgically resected lung adenocarcinomas were divided into three groups, solid predominant (solid component accounting for at least 50%), solid minor (solid component accounting for 5-45%) and solid negative. Patients' clinicopathological characteristics, disease free survival (DFS), overall survival (OS) and molecular alterations, including EGFR, KRAS, FGFR, etc., were analyzed. Of 1098 lung adenocarcinomas, 198 were solid predominant, 132 were solid minor, and 768 were solid negative. Solid positive patients, including solid predominant and solid minor, had significantly worse DFS (p < 0.0001) and OS (p < 0.0001) compared with solid negative group, so were solid minor patients (both p < 0.0001). Cox multivariate analysis revealed that solid positive pattern was an independent predictor for DFS [hazard ratio (HR) 1.495, 95% confidence interval (CI) 1.004-2.233; p = 0.034] and OS [HR 1.561, 95% CI 1.03-2.342; p = 0.016]. The frequency of FGFR fusions was significantly higher in solid positive lung adenocarcinomas than in solid negative group (1.5 vs. 0.3%, p = 0.048). The response rate to EGFR-tyrosine kinase inhibitors (TKIs) was 66.7% in EGFR-mutated solid positive patients after recurrence. This study represents the first comprehensive clinical investigation of solid component in lung adenocarcinomas, identifying solid positive pattern as an independent poor prognostic indicator in lung adenocarcinoma.
引用
收藏
页码:725 / 734
页数:10
相关论文
共 28 条
[1]   Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer [J].
Brooks, A. Nigel ;
Kilgour, Elaine ;
Smith, Paul D. .
CLINICAL CANCER RESEARCH, 2012, 18 (07) :1855-1862
[2]   Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors [J].
Calvo, Emiliano ;
Baselga, Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) :2158-2163
[3]   HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [J].
Cappuzzo, F ;
Bemis, L ;
Varella-Garcia, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2619-2621
[4]  
Chen Z, 2014, INT J CLIN EXP PATHO, V7, P8039
[5]   The New Lung Cancer Staging System [J].
Detterbeck, Frank C. ;
Boffa, Daniel J. ;
Tanoue, Lynn T. .
CHEST, 2009, 136 (01) :260-271
[6]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[7]   Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma [J].
Gu, Jie ;
Lu, Chunlai ;
Guo, Jing ;
Chen, Lingli ;
Chu, Yiwei ;
Ji, Yuan ;
Ge, Di .
JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (05) :474-480
[8]   Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma [J].
Hung, Jung-Jyh ;
Jeng, Wen-Juei ;
Chou, Teh-Ying ;
Hsu, Wen-Hu ;
Wu, Kou-Juey ;
Huang, Biing-Shiun ;
Wu, Yu-Chung .
ANNALS OF SURGERY, 2013, 258 (06) :1079-1086
[9]  
JEMAL A, 2011, CA-CANCER J CLIN, V61, P134, DOI [DOI 10.3322/caac.20115, DOI 10.3322/CAAC.20107]
[10]   Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer [J].
Kwak, Eunice L. ;
Bang, Yung-Jue ;
Camidge, D. Ross ;
Shaw, Alice T. ;
Solomon, Benjamin ;
Maki, Robert G. ;
Ou, Sai-Hong I. ;
Dezube, Bruce J. ;
Jaenne, Pasi A. ;
Costa, Daniel B. ;
Varella-Garcia, Marileila ;
Kim, Woo-Ho ;
Lynch, Thomas J. ;
Fidias, Panos ;
Stubbs, Hannah ;
Engelman, Jeffrey A. ;
Sequist, Lecia V. ;
Tan, WeiWei ;
Gandhi, Leena ;
Mino-Kenudson, Mari ;
Wei, Greg C. ;
Shreeve, S. Martin ;
Ratain, Mark J. ;
Settleman, Jeffrey ;
Christensen, James G. ;
Haber, Daniel A. ;
Wilner, Keith ;
Salgia, Ravi ;
Shapiro, Geoffrey I. ;
Clark, Jeffrey W. ;
Iafrate, A. John .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1693-1703